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ABSTRACT
Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase 
with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, 
Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical 
research system seems to prioritise innovation aimed at people of European descent. We 
found significant difficulties in assessing baseline demographics in clinical trials for COVID-19 
vaccines, displaying a lack of transparency in reporting. Further, we found that most of these 
trials take place in high-income countries, with only 25 of 219 trials (11.4%) taking place in 
lower middle- or low-income countries. Trials for the current best vaccine candidates 
(BNT162b2, ChadOx1, mRNA-173) recruited 80.0% White participants. Underrepresentation 
of BAME groups in medical research will perpetuate historical distrust in healthcare processes, 
and poses a risk of unknown differences in efficacy and safety of these vaccines by pheno-
type. Limiting trial demographics and settings will mean a lack of global applicability of the 
results of COVID-19 vaccine trials, which will slow progress towards ending the pandemic.
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Background
Severe acute respiratory syndrome coronavirus 
(SARS-CoV-2) spread remains uncontrolled in 191 
countries, with devastating consequences for liveli-
hoods and wellbeing. It has become clear that cor-
onavirus disease 2019 (COVID-19) mortality and 
morbidity increases with socioeconomic depriva-
tion. Due to centuries of systemic racism, socio-
economic health gradients have formed along racial 
lines [1]. Reflecting a trend seen globally, the mor-
tality rate from COVID-19 in the UK is over twice 
as high in the most deprived areas (3.1 compared 
to 1.4 per 100,000), with Black people four times 
more likely to die from coronavirus infection than 
White [2]. There are various socioeconomic and 
biomedical reasons that marginalised demographics 
in Western societies, in particular Black, Asian and 
minority ethnic (BAME) groups, bear 
a disproportionate case-load and a higher rate of 
severe disease [3].
Despite the extra risk BAME groups face in the 
pandemic, there is a lack of consideration in science 
and therefore a lack of protection in policy. 
Systematic neglect of ethnic diversity in medical 
research is historically displayed by consistent 
under-inclusion of non-White ethnic groups in clin-
ical trials across all specialties [4]. This stems from 
clinical trials being set in Global North countries 
with largely affluent populations of European des-
cent. Trial participants living largely secure, urban 
lifestyles may respond differently to healthcare 
interventions compared to the majority of the 
world population [4]. Research should be equitable 
to provide support for equal health outcomes 
between demographics; representation in medical 
research should therefore be adjusted to the risk of 
COVID-19 infection and severe disease course. 
Currently, the large proportion of COVID-19 
research on public health interventions and technol-
ogies may not be globally transferable [5].
As a result of historical unethical treatment and 
cyclical neglect of BAME groups in clinical trials, 
more barriers to engagement by these groups in 
medical research exist than ever before and remedial 
mechanisms have become complex [6]. Here we 
report on the difficulties collecting evidence on 
demographic imbalances in COVID-19 vaccine 
research, provide a snapshot of participant demo-
graphics in trials for the main vaccine candidates, 
and discuss the implications of the lack of equity 
and transparency. We hope this commentary pro-
vides some incentive for greater resolve in the med-
ical community to reverse the effects of centuries of 
structural racism in medical research and healthcare.
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Estimating the ethnic representation gap in 
COVID-19 vaccine trial participants
It is very difficult to get an accurate estimation of the 
scale of inequality in vaccine trial recruitment as 
there are no appropriate systems in place to report 
the demographics of clinical trial participants. 
Illustrating this issue, clinicaltrials.gov, the largest 
trial registry, does not demand or enable reporting 
of participant demographics beyond age and sex. We 
attempted to review demographics in vaccine trials 
listed on eu.trialstracker.net and covid19.trialstracker. 
net on 19/09/2020. We contacted clinical trial lead 
investigators between 01/11/2020 and 01/12/2020 
with a form to record gender, ethnicity, age, and 
socioeconomic status of trial participants. Responses 
were only received from two clinical trials after fol-
low-up, with no response from the other 194 trials. It 
was therefore impossible to conduct a comprehensive 
analysis of the demographic diversity of participants 
in these trials. Clinical trial registries having no 
requirement for detailed demographic reporting 
exemplify dangerous disregard of ethnicity and social 
circumstances when testing novel health technolo-
gies. Information on the demographics of partici-
pants in vaccine trials is therefore largely limited to 
academic publications which are often slow or absent.
From analysing the locations in which COVID-19 
vaccine trials are being conducted (219 as of 02/12/ 
2020), it is clear the geographical distribution of trials 
across the globe is skewed. Clinical trials were dis-
proportionately lacking in parts of Asia and the 
Pacific, and all of Africa and South America. China 
is involved in most trials, 27 (12.3%), followed by the 
USA with 20 (9.1%) (Figure 1). One hundred and 
ninety-four trials (88.6%) were carried out in upper- 
middle or high-income countries. Twenty-three 
(10.5%) were carried out in lower-middle-income 
countries and only 2 trials (0.9%) were carried out 
in low-income countries (Guinea-Bissau and Kenya). 
There was an extreme paucity of clinical trials being 
conducted in central and south-east Asia (Figure 2).
Additionally, we conducted a brief review of clin-
icaltrials.gov on 02/01/2021 for registered clinical 
trials of vaccines in final stages of development with 
baseline demographic results available in the aca-
demic literature. This search returned 2 trials for 
Pfizer/BNT162b2 (n = 18,950) [7,8], 3 for 
AstraZeneca/ChAdOx1 (n = 12,021) [9], and 2 for 
Moderna/mRNA-1273 (n = 15,111) [10–12] with 
baseline demographic results available. These trials 
took place in the UK, US, Brazil and South Africa. 
Of a total of 46,082 trial participants across these 8 
trials, 36,857 (80.0%) were White, 4,495 (9.8%) were 
Black, 1,897 (4.1%) were Asian and 2,883 (6.1%) were 
registered under another ethnicity (Figure 2).
Why a lack of diversity in medical research 
matters
As we have shown, clinical trials for COVID-19 vac-
cines take place largely in Global North nations and 
under-recruit non-White participants. Though clini-
cal trials for these three vaccines recruited partici-
pants in proportion to demographics in their 
national settings, they do not represent demographics 
most affected by COVID-19 globally. A notable 
exception is the AstraZeneca/ChadOx1 vaccine, for 
which a trial was carried out in South Africa with 
70.8% Black participants [9]. Still, limited variety in 
trial location and recruiting participants 
Figure 1. Global distribution of COVID-19 vaccine trials. (02/12/2020).
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representative of high-income settings will vastly 
reduce the applicability of findings from these clinical 
trials to the real world. Differences in mortality rates 
are likely to become more unequal as a new wave of 
COVID-19 reaches Global South countries with weak 
healthcare infrastructure and limited access to water, 
sanitation, and hygiene facilities [13]. Marginalised 
populations in high- and middle-income countries 
are already being increasingly affected, as infection 
burden shifts from the globetrotting rich to the more 
deprived [14].
Conducting trials mainly in high-income settings 
means that problems with the supply chain, storage, 
and access in resource-poor countries can easily be 
overlooked. The current best vaccine candidates, 
based on novel mRNA technologies, require cold 
chain storage and multiple-dose regimens demanding 
access to trained healthcare professionals and appro-
priate healthcare system planning. This puts up huge 
barriers of obtainment and expensive operations for 
countries in the Global South. Few, if any, low- 
income countries will have adequate healthcare infra-
structure for widescale distribution of these technol-
ogies, even if well-stocked [5]. Our best hope of 
reducing inequality in mortality and ending the pan-
demic is still through global distribution of vaccines 
that work for everyone, everywhere. However, unless 
novel vaccines are tested on demographics and in 
settings more representative of the global population, 
there is no guarantee of suitability, equivalent effi-
cacy, or safety across different contexts. We will pro-
ceed to explain the dangers of a lack of equitable 
recruitment, before discussing some potential recom-
mendations for change.
While no postulated genetic mechanism, predis-
position, or socioeconomic score completely explain 
the demographic imbalance in mortality, it is unde-
niably a consequence of a complex web of modifiable 
and non-modifiable risk factors [3]. Disproportionate 
infection risk in socioeconomically disadvantaged 
groups may result from insecure housing or work, 
causing overcrowding, difficulty isolating, or inability 
to discontinue the use of public transport. These 
problems are further compounded by language and/ 
or cultural barriers in health education, disempower-
ing preventive behaviour. Just as these lifestyle ele-
ments bolster contagion, they may also reduce 
adherence to strict clinical trial protocols, reducing 
the real-world efficacy of vaccines compared to clin-
ical trials. Recruiting populations with lower capacity 
to access healthcare in research would help to inform 
potential remedial mechanisms such as outreach pro-
grams, travel reimbursement schemes, or online edu-
cation tools, which may serve to enhance vaccine 
uptake.
Socioeconomic insecurity also increases the like-
lihood of behaviours which may worsen disease 
severity, such as smoking, drinking, lack of exercise, 
and poor diet. Social determinants also affect immu-
nomodulation as a result of chronic stress, as well as 
causing predisposition to cardiometabolic disease 
[15]. Descendants of Afro-Caribbean and South 
Asian diasporas in high-income countries are also at 
higher risk of cardiometabolic disorders [16]. Many 
of these risks are proven to make COVID-19 disease 
course faster and more severe [17]. Due to the under- 
inclusion of these groups, any interplay between these 
risk factors for comorbidity and vaccination efficacy 
is difficult to assess.
Correlations between severe COVID-19 in BAME 
demographics and certain genes have been postu-
lated. Current theories for this include genetic poly-
morphisms to the angiotensin-converting enzyme-2 
receptor, to which SARS-CoV-2 binds, and variation 
in human leukocyte antigen, which impact the 
immune response [18,19]. Equally, these same 
mechanisms may potentiate a better immune 
response, protecting BAME populations from severe 
disease. In such a new field, we cannot yet know the 
effects of ethnicity on response to COVID-19 infec-
tion. Similarly, it is difficult to foresee whether geno-
typic variability in vaccine response may also affect 
the safety and efficacy of potential COVID-19 vac-
cines. In previous cases where adverse event rates 
differ by ethnicity for other medications, such as 
lactic acidosis in black women on stavudine, dispa-
rities were not revealed until years after licensing 
because of a lack of ethnic diversity in clinical trial 
recruitment [20–22].
As a result of non-inclusive medical research, trust 
in vaccines may be diminished in minority groups, 
causing difficulty with clinical trial engagement and 
subsequent vaccine uptake [6]. This distrust stems 
from the long history of unethical medical research 
conducted amongst minority groups, whilst continu-
ing unequal and delayed access to healthcare rein-
forces this tendency today. Nuanced sociocultural 
intolerance for consideration of minority ethnic 
Figure 2. Proportion of clinical trial participants by ethnicity 
in vaccine trials for Pfizer/BNT162b2, Astrazeneca/ChadOx1 
and Moderna/mRNA-1273.
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groups throughout healthcare systems exacerbates 
disengagement from treatment, with negative impacts 
on health-seeking behaviour in minority ethnic com-
munities causing detriment to long-term health goals. 
Indeed, in a UK study carried out in 2020, vaccine 
hesitancy was associated with lower education, lower- 
income and minority ethnic grouping [23].
As shown by our trial distribution map (Figure 2), 
there is little engagement with vaccine trials in low- 
income countries. This could be because researchers 
shy away from ethical issues raised by trials con-
ducted in low-middle income countries to capitalise 
on the cheap resources and labour, and easy avail-
ability of participants. The updated Declaration of 
Helsinki includes recommendations on post-trial 
access to technologies for clinical trial participants, 
addressing a key injustice [24]. However, without the 
necessary regulations, there is no guarantee of afford-
ability and access to health innovations in the context 
that the trials were conducted in [25]. For example in 
South Africa, where Phase 3 ChadOx1 nCoV-19 trials 
were conducted by the University of Oxford, the 
government is paying more per vaccine dose than 
high-income countries in the European Union [26]. 
International collaboration and multilateralism 
regarding vaccine clinical trials has been sparse in 
the pandemic response. Research institutions devel-
oping vaccine technologies for COVID-19 in high- 
income countries are rarely engaging researchers in 
Global South settings. In order for clinical trials to 
represent the global population, the medical commu-
nity must prove its commitment to the health of 
marginalised groups, within and beyond the pan-
demic. A good place to start is with the assurance 
that COVID-19 vaccines are designed for all ethni-
cities and suited to any setting. These assurances can 
only be achieved by ingraining researchers local to all 
affected regions in the research process, as a stepping- 
stone to achieving fairer recruitment and 
distribution.
Recommendations
In order to fully measure the inequity in vaccine 
research, transparency on demographics and partici-
pant diversity in clinical trials for COVID-19 vaccines 
must improve to ensure that findings are valid glob-
ally. Currently, clinical trial investigators have no 
requirement to report enrolment strategies or ensure 
diverse recruitment. Mandatory reporting of recruit-
ment strategies to guarantee diversity in ethnicity 
would allow early evaluation of external validity and 
encourage more equitable, representative, and applic-
able research. Social determinants of health should 
also be reported through the use of metrics such as 
employment status.
Clinical trials are not being conducted in settings 
broad enough to inform global roll-out. While 
increasing transparency of recruitment methods and 
demographics reporting will help to show the knowl-
edge gap, of themselves they are not solutions. We 
must not only conduct clinical trials more equitably 
but begin to strategically conduct trials in varied 
geographical settings, engaging researchers from 
a wider range of institutions. Concerns around the 
ethics of clinical trials carried out in low-income 
countries need to be assuaged by guidelines that 
secure post-trial access while encouraging research, 
as trials conducted solely overseas do not currently 
require ethical approval from the UK Research Ethics 
Committee [27]. To ensure that health technologies 
become accessible for participant groups once mar-
keted, we propose a suitability assessment to take 
place before the trial, with consideration of future 
distribution of technologies within the existing health 
infrastructure. This must take place with better 
engagement of Global South Institutions in policy 
setting and research.
Conclusion
The impacts of COVID-19 are unequally distributed 
amongst socioeconomic classes and ethnic groups. In 
spite of these disparities, the health technologies we 
are creating are neither researched effectively in 
BAME groups nor address healthcare infrastructure 
challenges in resource-limited settings. Furthermore, 
transparency in COVID-19 vaccine trial recruitment 
and demographics reporting is poor. To ensure we 
develop a vaccine that works for everyone, we need 
equity in evidence and access. Including BAME 
groups in medical research should be a priority now 
and beyond the pandemic.
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Paper context
Black, Asian and Minority ethnic groups bear 
a disproportionate caseload of severe disease in the 
COVID-19 pandemic. These groups are underrepresented 
in medical research. COVID-19 vaccine trial equity is 
therefore important to ensure applicability. We show diffi-
culties conducting secondary analysis of vaccine trials, 
unequal geographical trial distribution (88.6% upper- 
middle or high-income countries) and imbalanced ethnic 
demographics for the current best vaccine candidates 
(80.0% White participants). These limited settings and 
demographics will weaken our pandemic response.
Disclaimer
As this paper was written in the UK, we have used the term 
Black, Asian and Minority Ethnicities (BAME), 
a commonly used and widely recognised acronym, to 
describe ethnicity. Where distinction is required, we have 
additionally used the terms Black, White and Asian.
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